![Martin Gouldstone](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 5 179 $ al 31/05/2026
Martin John Gouldstone is Chief Executive Officer & Director at Oncimmune Holdings Plc since 2023.
He is Chief Executive Officer at Oncimmune Germany.
GmbH.
He is Independent Non-Executive Chairman at ValiRx Plc since 2024.
He is Independent Non-Executive Director at hVIVO Holdings Ltd. since 2022.
Former roles include Independent Non-Executive Director at hVIVO PLC from 2022 to 2025.
Director at Novara Therapeutics Ltd. Director-Corporate Advisory & Head-Life Sciences at BDO UK LLP from 2015 to 2017.
Director-Business Development at Sareum Ltd. from 2006 to 2008.
Director at Orthopaedic Research UK from 2019 to 2024.
Partner at Results Healthcare from 2017 to 2018.
Chief Business Development Officer at Arcturis Data Ltd. from 2021 to 2022.
Global Senior Vice President-Business Development at Owkin, Inc. Chief Business Officer at BenevolentAI SA from 2018 to 2019.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
VALIRX PLC 0,27 % | 21/11/2025 | 1.969.231 ( 0,27 % ) | 5 179 $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| ONCE HLDG | Director Ejecutivo | 01/08/2023 |
| HVIVO PLC | Director/Miembro de la Junta | 01/06/2022 |
| VALIRX PLC | Presidente | 25/07/2024 |
Oncimmune Germany GmbH
 Oncimmune Germany GmbH BiotechnologyHealth Technology Develops antibody and autoantibody biomarker discovery platform | Director Ejecutivo | - |
| Empresas | Cargo | Fin |
|---|---|---|
| HVIVO PLC | Director/Miembro de la Junta | 05/06/2025 |
Orthopaedic Research UK
 Orthopaedic Research UK Miscellaneous Commercial ServicesCommercial Services Provides business support services | Director/Miembro de la Junta | 01/03/2024 |
| SENSYNE HEALTH PLC | Corporate Officer/Principal | 01/05/2022 |
| BENEVOLENTAI S.A. | Corporate Officer/Principal | 01/01/2019 |
Results Healthcare
 Results Healthcare Investment ManagersFinance Provides advisory services | Corporate Officer/Principal | 01/06/2018 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 12 |
|---|---|
ValiRx Plc
 ValiRx Plc Pharmaceuticals: MajorHealth Technology Develops novel technologies and products in oncology therapeutics and diagnostics | Health Technology |
hVIVO Holdings Ltd.
 hVIVO Holdings Ltd. Miscellaneous Commercial ServicesCommercial Services Provides medical research services | Commercial Services |
Sareum Ltd.
 Sareum Ltd. Drugstore ChainsRetail Trade Provides drug discovery services | Retail Trade |
Results Healthcare
Results Healthcare Investment ManagersFinance Provides advisory services | Finance |
Oncimmune Holdings Plc
 Oncimmune Holdings Plc BiotechnologyHealth Technology Provides cancer detection and diagnosis services | Health Technology |
Orthopaedic Research UK
Orthopaedic Research UK Miscellaneous Commercial ServicesCommercial Services Provides business support services | Commercial Services |
Owkin, Inc.
 Owkin, Inc. Packaged SoftwareTechnology Services Develops AI technology that accelerates drug discovery by combining multimodal patient data and large language models | Technology Services |
Sensyne Health Ltd.
 Sensyne Health Ltd. Miscellaneous Commercial ServicesCommercial Services Provides statistical analyses and advanced insights to the healthcare industry | Commercial Services |
BDO UK LLP
 BDO UK LLP Miscellaneous Commercial ServicesCommercial Services Provides tax, audit & assurance, advisory and business outsourcing services | Commercial Services |
hVIVO PLC
 hVIVO PLC Miscellaneous Commercial ServicesCommercial Services Provides pharmaceutical development services | Commercial Services |
Oncimmune Germany GmbH
Oncimmune Germany GmbH BiotechnologyHealth Technology Develops antibody and autoantibody biomarker discovery platform | Health Technology |
BenevolentAI SA
 BenevolentAI SA Packaged SoftwareTechnology Services Develops AI drug discovery platform to accelerate biopharma drug discovery | Technology Services |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
